GMED, US3795772082

Globus Medical stock gained 1.60 percent on October 2 after RBC cut its target

Published on 10/04/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC cut its GMED target from USD 115 to USD 85 on October 1, 2026. Second-quarter revenue reached USD 789.61 million, with reported EPS at USD 1.34.

GMED, US3795772082, Illustration mit AI erstellt.

Globus Medical stock (ISIN US3795772082) closed at USD 75.60 on the NYSE on October 2, 2026, up 1.60 percent from the previous close of USD 74.41. The latest signal came from Markets Insider, which reported on October 1, 2026, that RBC Capital cut its target from USD 115 to USD 85 while maintaining an Outperform rating.

RBC trims target to USD 85

The revised RBC target lies 12.2 percent above the October 2 price. The bank linked its more cautious view to second-half risks in two business areas and volatility in spine procedures, according to Markets Insider.

The lower target does not erase the gap between the share price and the broader analyst view. MarketBeat reported on September 29, 2026, that 17 analysts held a Moderate Buy consensus, with nine Buy ratings, three Strong Buy ratings and five Holds. The average 12-month target was USD 101.77, which lies 34.6 percent above the October 2 price.

Q2 revenue reached USD 789.61 million

Globus Medical's second-quarter 2026 revenue rose 5.9 percent year over year to USD 789.61 million, while reported EPS came in at USD 1.34 against a USD 1.10 consensus estimate. The figures were reported by MarketBeat in its September 29, 2026 coverage of the company.

The latest quarter therefore combines revenue growth with an earnings beat, but the market is also weighing procedure volatility and the effect of the Nevro business on growth. Globus Medical operates across spine, orthopedic trauma, joint reconstruction, regenerative biomaterials and enabling technologies, including robotic and image-guided systems, according to the company's investor-relations profile.

Stock remains below its yearly high

GMED traded between USD 74.42 and USD 76.16 on October 2, 2026, with volume of 1,310,223 shares. Its 52-week range was USD 56.50 to USD 101.40, leaving the stock 25.4 percent below the yearly high.

The company had a market capitalization of USD 10.2 billion as of October 2, 2026. The next reported earnings date is November 5, 2026.